Floatz logo

Mirvetuximab Soravtansine

Primary Peritoneal Carcinoma

AbbVieantibody_drug_conjugatePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
69/ 100
Competitive Position
73/ 100

Competitive context

148 Active assets in the Primary Peritoneal Carcinoma cohort.

Asset / SponsorPhaseRating
Cis-Diamminedichloroplatinum Ii
GOG Foundation
Phase 3BBB
Carboplatin
University of Washington
Phase 3BBB
Adriamycin
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3BBB
Nogitecan
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3BBB
Pegfilgrastim
TORL Biotherapeutics, LLC
Phase 2/3BBB

View all 50 →

Same molecule, other indications

Mirvetuximab Soravtansine is also rated in:

ovarian carcinomaActive
BBB
Indicative · Phase 3
76 / 100
View asset →
fallopian tube cancerActive
BB
Indicative · Phase 3
70 / 100
View asset →
peritoneum cancerActive
BB
Indicative · Phase 3
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →